Anti-tumor necrosis factor-α therapy of rheumatoid arthritis

Advances in Immunology

Volumn 64, Issue , 1997, Pages 283-350

  Feldmann, Marc ^a   Elliott, Michael J ^a   Woody, James N ^b   Maini, Ravinder N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AUTOIMMUNITY; CARDIOVASCULAR RISK; HEMATOPOIESIS; HLA SYSTEM; HUMAN; IMMUNOTHERAPY; INFECTION SENSITIVITY; LIFE EXPECTANCY; PERICARDITIS; PLEURISY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0030996312     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (258)

1. Aboulafia, D., Miles, S. A., Saks, S. R., and Mitsuyasu, R. T. (1989). Intravenous recombinant tumor necrosis factor in the treatment of AIDS-related Kaposi's sarcoma. /. Acquired Immune Deficiency Syndrome 2.
2. Agosti, J. M., Fisher, C. J., Opal, S. M., Lowry, S. F., Balk, R. A., and Sadoff, J. C. (1994). Treatment of patients with sepsis syndrome with soluble TNF receptor (sTNFR). Proc. 34th Annu. ICAAC 34, 65.
3. Akahane, K., Hosoi, T., Urabe, A., Kawakami, M, and Takaku, F. (1987). Effects of recombinant human tumor necrosis factor (rhTNF) on normal human and mouse hemopoietic progenitor cells. Int. J. Cell Cloning 5, 16-26.
4. Akira, S., Taga, T., and Kishimoto, T. (1993). Interleukin-6 in biology and medicine. Adv. Immunol. 54, 1-78.
5. Allard, S. A., Muirden, K. D., and Maim, R. N. (1991). Correlation of histopathological features of pannus with patterns of damage in different joints in rheumatoid arthritis. Ann. Bheum. Dis. 50, 278-283.
6. Alvaro-Garcia, J. M., Zvaifler, N. J., Brown, C. B., Kaushansky, L., and Firestein, G. S. (1991). Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and TNF-alpha. J. Immunol. 146, 3365-3371.
7. Arend, W. P. (1993). Interleukin-1 receptor antagonist. Adv. Immunol. 54, 167-227.
8. Bach, J.-F., and Chatenoud, L. (1995). Immunosuppression in insulin-dependent diabetes mellitus: From cellular selectivity towards autoantigen specificity. In "Selective Immunosuppression: Basic Concepts and Clinical Applications" (L. Adorini, Ed.), Vol. 60, pp. 32-47. Karger, Basel.
9. Bakker, N. P. M., van Erck, M. G. M., Botman, C. A. D., Jonker, M., and Hart, L. A. (1991). Collagen induced arthritis in an outbred group of rhesus monkeys comprising responder and non responder animals. Relationship between course of arthritis and collagen specific immunity. Arthr. Rheum. 34, 616-624.
10. Bannwarth, B., Vernhes, J. P., Schaeverbeke, T., and Dehais, J. (1995). The facts about methotrexate in rheumatoid arthritis. Rev. Rheum., 62, 471-473.
11. Barker, D. J. (1995). Fetal origins of coronary heart disease. Br. Med. J. 311, 171-174.
12. Baumgartner, S., Moreland, L. W., Schiff, M. W., Tindell, E., Fleischman, R. M., Weaver, A., Ettlinger, R. E., Grosler, B. L., Katz, R. S., Skosey, J. L., Lies, R. B., Robinson, A., and Blosch, C. M. (1996). Double-blind, placebo-controlled trend of tumor necrosis factor receptor (p80) fusion protein (TNFR:Fc) in active rheumatoid arthritis. Arth. Rheum. 39, S74. [Abs. 283]
13. Bemelmans, M. H. A., Gouma, D. J., and Buurman, W. A. (1993). LPS-induced sTNFreceptor release in vivo in a murine model. J. Immunol. 151, 5554-5562.
14. Bendtzen, K., Morling, N., Fomsgaard, A., Svenson, M., Jakobsen, B., Odum, N., and Svejgaard, A. (1988). Association between HLA-DR2 and production of tumour necrosis factor α and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand. J. Immunol. 28, 599-606.
15. Benjamin, R. J., and Waldmann, H. (1986). Induction of tolerance by monoclonal antibody therapy. Nature 320, 449-451.
16. Bertolini, D. R., Nedwin, G. E., Bringman, T. S., Smith, D. D., and Mundy, G. R. (1986). Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factor. Nature 319, 516-518.
17. Beutler, B., and Cerami, A. (1989). The biology of cachectin/TNF-A primary mediator of the host response. Annu. Rev. Immunol. 7, 625-655.
18. Beutler, B. A., Milsark, I. W., and Cerami, A. (1985). Cachectin/tumor necrosis factor: Production, distribution, and metabolic fate in vivo. J. Immunol. 135, 3972-3977.
19. Birkedal-Hansen, H., Moore, W. G., Bodden, M. K., Windsor, L. J., Birkedal-Hansen, B., DeCarlo, A., and Engler, J. A. (1993). Matrix metalloproteinases: A review. Crit. Rev. Oral Biol. Med. 4, 197-250.
20. Blake, D. R., Unsworth, J., Outhwaite, J. M., Morris, C. J., Merry, P., Kidd, B. L., Ballard, R., Gray, L., and Lunec, J. (1989). Hypoxic-reperfusion injury in the inflamed human joint. Lancet 1, 289-293.
21. Boerbooms, A. M. T., Kerstens, P. J. S. M., Van Loehhout, J. W. A., Mulder, J., and Van de Putte, L. B. A. (1995). Infections during low-dose methotrexate treatment in rheumatoid arthritis. Sem. Arthr. Rheum. 24, 411-421.
22. Bottazzo, G. F., Pujol-Borrell, R., Hanafusa, T., and Feldmann, M. (1983). Hypothesis: Role of aberrant HLA-DR expression and antigen presentation in the induction of endocrine autoimmunity. Lancet 2, 1115-1119.
23. Boyd, H. K., Lappin, R. J., and Bell, A. L. (1991). Evidence for impaired erythropoietin response to anaemia in rheumatoid disease. Br. J. Rheumatol. 30, 255-259.
24. Braegger, C. P., Nicholls, S., Murch, S. H., Stephens, S., and MacDonald, T. T. (1992). Tumour necrosis factor alpha in stool as a marker of intestinal inflammation [see comments]. Lancet 339, 89-91.
25. Breese, E. J., Michie, C. A., Nicholls, S. W., Murch, S. H., Williams, C. B., Domizio, P., Walker-Smith, J. A., and MacDonald, T. T. (1994). Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106, 1455-1466.
26. Brennan, F. M., Chantry, D., Jackson, A., Maini, R., and Feldmann, M. (1989). Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244-247.
27. Brennan, F. M., Chantry, D., Turner, M., Foxwell, B., Maini, R. N., and Feldmann, M. (1990a). Transforming growth factor-β in rheumatoid arthritis synovial tissue: Lack of effect on spontaneous cytokine production in joint cell cultures. Clin. Exp. Immunol. 81, 278-285.
28. Brennan, F. M., Zachariae, C. O., Chantry, D., Larsen, C. G., Turner, M., Maini, R. N., Matsushima, K., and Feldmann, M. (1990b). Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur. J. Immunol. 20, 2141-2144.
29. Brennan, F. M., Gibbons, D., Cope, A., Katsikis, P., Maini, R. N., and Feldmann, M. (1995). TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: Evidence of feedback control of TNF action. Scand. J. Immunol. 421, 58-165.
30. Brennan, F. M, Browne, K. A., Green, P. A., Jasper, J.-M., Maini, R. N. L., and Feldmann, M. (1997). Reduction in serum matrix metalloproteinase 1 and 3 in rheumatoid arthritis patients following anti-TNFa (cA2) therapy. Br. J. Rheum, (in press).
31. Bresnihan, B., Mulherin, D., and FitzGerald, O. (1995). Synovial pathology and articular erosion in rheumatoid arthritis. Rheumatol. Eur. 24(Suppl.), 158-160.
32. Brown, A. S., and Martin, J. F. (1994). The megakaryocyte platelet system and vascular disease. Eur. J. Clin. Invest. 24(SuppI. 1), 99-115.
33. Buchan, G., Barrett, K., Fujita, T., Taniguchi, T., Maini, R., and Feldmann, M. (1988a). Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-γ. Clin. Exp. Immunol. 71, 295-301.
34. Buchan, G., Barrett, K., Turner, M., Chantry, D., Maini, R. N., and Feldmann, M. (1988b). Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: Prolonged production of IL-lα. Clin. Exp. Immunol. 73, 449-455.
35. Buchanan, W. W. (1994). Rheumatoid arthritis: Another New World disease? Sem. Arthr. Rheum. 23, 289-294.
36. Burstein, S. A., Downs, T., Friese, P., Lynam, S., Anderson, S., Henthorn, J., Epstein, R. B., and Savage, K. (1992). Thrombocytopoiesis in normal and sublethally irradiated dogs: Response to human interleukin-6. Blood 80, 420-428.
37. Butler, D. M., Maini, R. N., Feldmann, M., and Brennan, F. M. (1995). Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNFa antibody with the IL-1 receptor antagonist. Eur. Cytokine Network 6, 225-230.
38. Buttle, D. J. (1994). Lysosomal cysteine endopeptidases in the degradation of cartilage and bone. In "Immunopharmacology of Joints and Connective Tissue" (E. Davies and J. T. Dingle, Eds.), pp. 119-128. Academic Press, London.
39. Carlos, T. M., and Harlan, J. M. (1994). Leukocyte-endothelial adhesion molecules. Blood 84, 2068-2101.
40. Charles, P., Elliott, M. J., Davis, D., Potter, A., Kalden, J., Antoni, C, Breedveld, F., Smolen, J. S., Gabriele, E., Woody, J. N., Feldmann, M., and Maini, R. N. (1997). Regulation of cytokines and acute phase proteins following TNFα blockade in rheumatoid arthritis. Submitted for publication.
41. Charles, P., Potter, A., Elliott, M., Cope, A., Woody, J., Feldmann, M. L., and Maini, R. N. (1995). Regulation of STNF Rad IL-6 following TNF blockade in RA: In vivo evidence for a cytokine cascade. Arth. Rheum. 38, S352. [abstract]
42. Chikanza, I. C, Petrou, P., Kingsley, G., Chrousos, G., and Panayi, G. S. (1992). Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthr. Rheum. 35, 1281.
43. Chiller, J. M., Habicht, G. S., and Weigle, W. O. (1970). Cellular sites of immunologic unresponsiveness. Proc. Natl. Acad. Sci. USA 65, 551-556.
44. Choy, E. H., Chikanza, I. C, Kingsley, G., Corrigall, V., and Panayi, G. S. (1992). Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand. J. Immunol. 36, 291-298.
45. Cohen, I. R. (1991). Autoimmunity to chaperones on the pathogenesis of arthritis and diabetes. Annu. Rev. Immunol. 9, 567-589.
46. Cohen, S. B. A., Katsikis, P. D., Chu, C. Q., Thomssen, H., Webb, L. M. C, Maini, R. N., Londei, M., and Feldmann, M. (1995). High level of IL-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthr. Rheum. 38,946-952.
47. Colville-Nash, P. R., and Scott, D. L. (1992). Angiogenesis and rheumatoid arthritis: Pathogenic and therapeutic implications. Ann. Rheum. Dis. 51, 919-925.
48. Conaghan, P. G., Quinn, D. I., Brooks, P. M., and Day, R. O. (1995). Hazards of low-dose methotrexate. Aust. NZJ. Med. 25, 670-673.
49. Cope, A., Aderka, D., Doherty, M., Engelmann, H., Gibbons, D., Jones, A. C., Brennan, F. M., Maini, R. N., Wallach, D., and Feldmann, M. (1992). Soluble tumour necrosis factor (TNF) receptors are increased in the sera and synovial fluids of patients with rheumatic diseases. Arthr. Rheum. 35, 1160-1169.
50. Cope, A. P., Londei, M., Chu, N. R., Cohen, S. B. A., Elliott, M. J., Brennan, F. M., Maini, R. N., and Feldmann, M. (1994). Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: Reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J. Clin. Invest. 94, 749-760.
51. Cush, J. J., Splawski, J. B., Thomas, R., McFarlin, J. E., Schulze-Koops, H., Davis, L. S., Fujita, K., and Lipsky, P. E. (1995). Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthr. Rheum. 38, 96-104.
52. Cutolo, M., Kirkham, B., Bologna, C, Sony, J., Scott, D., Brooks, P., Forre, O., Jain, R., Kuen, T., Markensea, J., Seibold, J., Sturrock, R., Veys, E., Edwards, J., Zang, M., Durrwell, L., Bisscheps, C, St. Clair, P., Milnarik, P., Baudin, M., and Van der Auwera, P. (1996). Loading/Maintenance doses approach to neutralization of TNF by lenercept in patients with rheumatoid arthritis treated for 3 months: Results of a double-blind placebo-controlled phase II trial. Arth. Reum. 39, S243. [abstract 1296]
53. Dale, D. C, and Petersdorf, R. G. (1973). Corticosteroids and infectious disease. Med. Clin. North Am. 57, 1277-1287.
54. Dayan, C. M, Londei, M., Corcoran, A. E., Grubeck-Loebenstein, B., James, R. F., Rapoport, B., and Feldmann, M. (1991). Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. Proc. Natl. Acad. Sci. USA 88, 7415-7419.
55. Deleuran, B. W., Chu, C. Q., Field, M., Brennan, F. M., Katsikis, P., Feldmann, M., and Maini, R. N. (1992). Localization of interleukin-lα:, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br. J. Rheumatol. 31, 801-809.
56. Derkx, B., Taminiau, J., Radema, S., Stronkhorst, A., Wortel, C, Tytgat, G., and van Deventer, S. (1993). Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 342, 173-174.
57. De Togni, P., Goellner, J., Ruddle, N. H., Streeter, P. R., Fick, A., Mariathasan, S., Smith, S. C, Carlson, R., Shornick, I. P., Strauss-Schoenberger, J., Russell, J. H., Karr, R., and Chaplin, D. D. (1994). Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264, 703-707.
58. Di Giovine, F. S., Nuki, G., and Duff, G. W. (1988). Tumour necrosis factor in synovial exudates. Ann. Rheum. Dis. 47, 768-772.
59. Dinarello, C. A., Cannon, J. G., Wolff, S. M., Bernheim, H. A., Beutler, B., Cerami, A., Figari, I. S., Palladino, M. A., and O'Connor, J. V. (1986). Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.J. Exp. Med. 163,1433-1450.
60. Dumonde, D. C, and Glynn, L. E. (1962). The production of arthritis in rabbits by an immunological reaction to fibrin. Br. J. Exp. Pathol. 43, 373-383.
61. Elliott, M. J., and Maini, R. N. (1994). New directions for biological therapy in rheumatoid arthritis. Int. Arch. Allergy Immunol. 104, 112-125.
62. Elliott, M. J., Maini, R. N., Feldmann, M., Long-Fox, A., Charles, P., Katsikis, P., Brennan, F. M., Walker, J., Bijl, H., Ghrayeb, J., and Woody, J. N. (1993). Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to rumor necrosis factor a. Arthr. Rheum. 36, 1681-1690.
63. Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C, Smolen, J. S., Leeb, B., Breedveld, F. C, Macfarlane, J. D., Bijl, H., and Woody, J. N. (1994a). Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105-1110.
64. Elliott, M. J., Maini, R. N., Feldmann, M., Long-Fox, A., Charles, P., Bijl, H., and Woody, J. N. (1994b). Repeated therapy with monoclonal antibody to tumour necrosis factor a (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125-1128.
65. Erhardt, C. C, Mumford, P. A., Venables, P. J. W., and Maini, R. N. (1989). Factors predicting a poor life prognosis in rheumatoid arthritis: An eight year prospective study. Ann. Rheum. Dis. 48, 7-13.
66. Evans, T. I., Han, J., Singh, R., and Moxley, G. (1995). The genotypic distribution of shared-epitope DRB1 alleles suggests a recessive mode of inheritance of the rheumatoid arthritis disease-susceptibility gene. Arthr. Rheum. 38, 1754-1761.
67. Fava, R. A., Olsen, N. J., Postlethwaite, A. E., Broadley, K. N., Davidson, J. M., Nanney, L. B., Lucas, C, and Townes, A. S. (1991). Transforming growth factor β1 (TGF-β1) induced neutrophil recruitment to synovial tissues: Implications for TGF-β-driven synovial inflammation and hyperplasia.J. Exp. Med. 173, 1121-1132.
68. Fava, R. A., Olsen, N. J., Spencer-Green, G., Yeo, K.-T., Yeo, T.-K., Berse, B., Jackman, R. W. Senger, D. R., Dvorak, H. F., and Brown, L. F. (1994). Vascular permeability factor/endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. 180, 334-346.
69. Feldmann, M., Brennan, F. M., Chantry, D., Haworth, C., Turner, M., Abney, E., Buchan, G., Barrett, K., Barkley, D., Chu, A., Field, M., and Maini, R. N. (1990). Cytokine production in the rheumatoid joint: Implications for treatment. Ann. Rheum. Dis. 49, 480-486.
70. Feldmann, M., Brennan, F. M., and Maini, R. N. (1996). Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397-440.
71. Fell, H. B., and Jubb, R. W. (1977). The effect of synovial tissue on the breakdown of articular cartilage in organ culture. Arthr. Rheum. 20, 1359-1371.
72. Ferrara, N., Houck, K., Jakeman, L., and Leung, D. W. (1992). Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrinol. Rev. 13, 18-32.
73. Firestein, G. S., and Zvaifler, N. J. (1990). How important are T cells in chronic rheumatoid synovitis? Arthr. Rheum. 33, 768-773.
74. Firestein, G. S., Xu, W.-D., Townsend, K., Broide, D., Alvaro-Gracia, J., Glasebrook, A., and Zvaifler, N. J. (1988). Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. Exp. Med. 168, 1573-1586.
75. Firestein, G. S., Berger, A. E., Tracey, D. E., Chosay, J. G., Chapman, D. L., Paine, M. M., Yu, C, and Zvaifler, N. J. (1992). IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J. Immunol. 149, 1054-1062.
76. Fisher, C, Jr., Opal, S. M., Dhainaut, J. F., Stephens, S., Zimmerman, J. L., Nightingale, P., Harris, S. J., Schein, R. M., Panacek, E. A., Vincent, J. L., et al. (1993). Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group [see comments]. Crit. Care Med. 21, 318-327.
77. Fong, Y., Tracey, K. J., Moldawer, L. L., Hesse, D. G., Manogue, K. B., Kenney, J. S., Lee, A. T., Kuo, G. C, Allison, A. C, Lowry, S. F., and Cerami, A. (1989). Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 170, 1627-1633.
78. Fontana, A., Hentgartner, H., Fehr, K., Grab, P. J., and Cohen, G. (1982). Interleukin-1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol. Int. 2,49-56.
79. Furst, D., Weisman, M, Paulus, H., Bulpitt, K., Weinblatt, M., Polisson, R., St. Clair, P., Milnarik, P., Baudin, M., Ludin, E., McAuliffe, T., Kahry, M.-R., Lesslauer, W., and Van de Auwera, P. (1996). Neutralization of TNF by lenercept (TNFR 55 TgGt, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: Results of a phase II trial. Arth. Rheum. 39, S243. [abstract 1295]
80. Gardner, D. L. (1994). Problems and paradigms in joint pathology. J. Anat. 184, 465-476.
81. Gearing, A. J. H., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., Leber, T. M., Mangan, M., Miller, K., Nayee, P., Owen, K., Patel, S., Thomas, W., Wells, G., Wood, L. M., and Woolley, K. (1994). Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370, 555.
82. Genain, C. P., Roberts, T., Davis, R. L., Nguyen, M.-H., Uccelh, A., Faulds, D., Li, Y., Hedgpeth, J., and Hauser, S. L. (1995). Prevention of autoimmune demyelination in nonhuman primates by a cAMP-specific pheosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA 92, 3601-3605.
83. Gordon, D. A., and Hastings, D. E. (1994). Clinical features: Early, progressive and late disease. In "Rheumatology" (J. H. Klippel and P. A. Dieppe, Eds.), Section 3, pp. 4.1-4.14. Mosby, London.
84. Gowen, M., Wood, D. D., Ihrie, E. J., McGuire, M. K. B., and Russell, R. G. (1983). An interleukin-1 like factor stimulates bone resorption in vitro. Nature 306, 378-380.
85. Gray, P. W., Aggarwal, B. B., Benton, C. V., Bringman, T. S., Henzel, W. J., Jarrett, J. A., Leung, D. W., Moffat, B., Ng, P., Svedersky, L. P., Palladino, M. A., and Nedwin, G. E. (1984). Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumor necrosis factor activity. Nature 312, 721-724.
86. Gregersen, P. K., Silver, J., and Winchester, R. J. (1987). The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to Rheumatoid arthritis. Arthr. Rheum. 30, 1205-1213.
87. Gulwani-Akolkar, B., Posnett, D. N., Janson, C. H., Grunewald, J., Wigzell, H., Akolkar, P., Gregersen, P. K., and Silver, J. (1991). T cell receptor V-segment frequencies in peripheral blood T cells correlate with human leukocyte antigen type. J. Exp. Med. 174, 1139-1146.
88. Han, J., Brown, T., and Beutler, B. (1990). Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level.J. Exp. Med. 171,465-475. [Published erratum appears inJ. Exp. Med. 171(3), 971-972, 1990]
89. Hasler, F., van de Putte, L., Dumont, E., Kneer, J., Bock, J., Dickenson, S., Lesslauer, W., and Van de Auwera, P. (1996). Safety and efficacy of TNF neutralization by lenercept in patients with rheumatoid arthritis exposed to a single dose. Arth. Rheum. 39, S243. [abstract 1291]
90. Hasler, F., van de Putte, L., Baudin, M., Lodin, E., Durrwell, L., McAuliffe, T., and van de Auwera, P. (1996). Chronic TNF neutralization (up to 1 year) by lenercept (TNFR 55 IgG 1, Ro 45-2081) in patients with rheumatoid arthritis: Results for open label extension of a double-blind single-dose phase I study. Arth. Rheum. 39, S243. [abstract 1292].
91. Hassfeld, W., Steiner, G., Hartmuth, K., Kolarz, G., Scherak, O., Grainger, W., Thumb, N., and Smolen, J. S. (1989). Demonstration of a new anti-nuclear antibody (anti-RA 33) that is highly specific for rheumatoid arthritis. Arthr. Rheum. 32, 1515-1520.
92. Haworth, C, Brennan, F. M., Chantry, D., Turner, M., Maini, R. N., and Feldmann, M. (1991). Expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) in rheumatoid arthritis: Regulation by tumour necrosis factor-α. Eur. J. Immunol. 21,2575-2579.
93. Herodin, F., Mestries, J. C, Janodet, D., Martin, S., Mathieu, J., Gascon, M. P., Pernin, M. O., and Ythier, A. (1992). Recombinant glycosylated human interleukin-6 accelerates peripheral blood platelet count recovery in radiation-induced bone marrow depression in baboons. Blood 80, 688-695.
94. Hill, P. A., Murphy, G., Docherty, A. J., Hembry, R. M., Millican, T. A., Reynolds, J. J., and Meikle, M. C. (1994). The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J. Cell Sci. 107, 3055-3064.
95. Hirano, T., Taga, T., Yasukawa, K., Nakajima, K., Nakano, N., Takatsuki, F., Shimizu, M., Murashima, A., Tsunasawa, S., Sakiyama, F., and Kishimoto, T. (1987). Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc. Natl. Acad. Sci. USA 84, 228-231.
96. Hirano, T., Matsuda, T., Turner, M., Miyasaka, N., Buchan, G., Tang, B., Sato, K., Shimizu, M., Maini, R., Feldmann, M., and Kishimoto, T. (1988). Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur. J. Immunol. 18,1797-1801.
97. Holmdahl, R., Tarkowski, A., and Jonsson, R. (1988). Immunogenetics of type II collagen autoimmunity and susceptibility to collagen arthritis. Immunology 65, 305-310.
98. Hopkins, S. J., Humphreys, M., and Jayson, M. I. (1988). Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1. Clin. Exp. Immunol. 72, 422-427.
99. Horneff, G., Burmester, G. R., Emmrieh, F., and Kalden, J. R. (1991). Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthr. Rheum. 34,129-140.
100. Hosaka, S., Akshoshi, T., Wada, C, and Kondo, H. (1994). Expression of the chemokine superfamily in rheumatoid arthritis. Clin. Exp. Immunol. 97, 451-457.
101. Isaacs, J. D., Watts, R. A., Hazleman, B. L., Hale, G., Keogan, M. T., Cobbold, S. P., and Waldmann, H. (1992). Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340, 748-752.
102. Ishida, H., Muchamuel, T., Sakaguchi, S., Andrade, S., Menon, S., and Howard, M. (1994). Continuous administration of anti-interleuldn 10 antibodies delays onset of autoimmunity in NZB/W Fl mice. J. Exp. Med. 179, 305-310.
103. Issekutz, A. C, Meager, A., Otterness, I., and Isskeutz, T. B. (1994). The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin. Exp. Immunol. 97, 26-32.
104. Jacob, C. O., and McDevitt, H. O. (1988). Tumour necrosis factor-alpha in murine autoimmune "lupus" nephritis. Nature 331, 356-358.
105. Jacob, C. O., Fronek, Z., Lewis, G. D., Koo, M., Hansen, J. A., and McDevitt, H. O. (1990). Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor α: Relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 87, 1233-1237.
106. Johnson, R. A., Waddelow, T. A., Caro, J., Oliff, A., and Roodman, G. D. (1989). Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 74, 130-138.
107. Jourdan, M., Bataille, R., Seguin, J., Zhang, X. G., Chaptal, P. A., and Klein, B. (1990). Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthr. Rheum. 33, 398-402.
108. Kaklamanis, P. M. (1992). Experimental animal models resembling rheumatoid arthritis. Clin. Rheum. 11, 41-47.
109. Katsikis, P., Chu, C. Q., Brennan, F. M., Maini, R. N., and Feldmann, M. (1994). Immunoregulatoryrole of interleukin 10 (IL-10) in rheumatoid arthritis.J. Exp. Med. 179,1517-1527.
110. Kavanaugh, A. F., Davis, L. S., Nichols, L. A., Norris, S. H., Rothlein, R., Scharschmidt, L. A., and Lipsky, P. E. (1994). Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthr. Rheum. 37, 992-999.
111. Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D., and Kollias, G. (1991). Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J. 10, 4025-4031.
112. Kehrl, J. H., Alvarez-Mon, M., Delsing, G. A., and Fauci, A. S. (1987a). Lymphotoxin is an important T cell derived growth factor for human B cells. Science 238, 1144-1146.
113. Kehrl, J. H., Miller, A., and Fauci, A. S. (1987b). Effects of tumor necrosis factor a on mitogen-activated human B cells. J. Exp. Med. 166, 786-791.
114. Kennedy-Stoskopf, S. (1989). Pathogenesis of lentivirus-induced arthritis: A review. Rheumatol. Int. 9, 129-136.
115. Klareskog, L., and Olsson, T. (1990). Autoimmunity to collagen II and myelin basic protein: Comparative studies in humans and rodents. Immunol. Rev. 118, 285-310.
116. Knight, D. M., Trinh, H., Le, J., Siegel, S., Shealy, D., McDonough, M., Scallon, B., Moore, A. M., Vilcek, J., Daddona, P., and Ghrayeb, J. (1993). Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30, 1443-1453.
117. Kobayashi, I., and Ziff, M. (1975). Electron microscopic studies of the cartilage-pannus junction in rheumatoid arthritis. Arthr. Rheum. 18, 475-483.
118. Koch, A. E., Burrows, J. C., Haines, G. K., Carlos, T. M., Harlan, J. M., and Leibovich, S. J. (1991). Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab. Invest. 64, 313-320.
119. Koch, A. E., Kunkel, S. L., Harlow, L. A., Johnson, B., Evanoff, H. L., Haines, G. K., Burdick, M. D., Pope, R. M., and Strieter, R. M. (1992). Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J. Clin. Invest. 90, 772-779.
120. Koch, A. E., Harlow, L. A., Haines, G. K., Amento, E. P., Unemori, E. N., Wong, W. L., Pope, R. M., and Ferrara, N. (1994a). Vascular endothelial growth factor: A cytokine-modulating endothelial function in rheumatoid arthritis. J. Immunol. 152, 4149-4156.
121. Koch, A. E., Kunkel, S. L., Harlow, L. A., Mazarakis, D. D., Haines, G. K., Burdick, M. D., Pope, R. M., Walz, A., and Strieter, R. M. (1994b). Epithelial neutrophil activating peptide-78: A novel chemotactic cytokine for neutrophiols in arthritis. J. Clin. Invest. 94, 1012-1018.
122. Koch, A. E., Halloran, M. M., Haskell, C. J., Shah, M. R., and Polverini, P. J. (1995). Angiogenesis mediated by soluble forms of E-selectin and vascular cells adhesion molecule-1. Nature 376, 517-519.
123. Lafyatis, R., Thomson, N. L., Remmers, E. R., Flanders, K. C, Roche, N. S., and Kim, S. J. (1989). Transforming growth factor-beta production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritis rats. Studies on secretion by synovial fibroblast-like cells and immunohistological localisation. J. Immunol. 143, 1142-1148.
124. Lahdevirta, J., Maury, C. P. J., Teppo, A.-M., and Repo, H. (1988). Elevated levels of circulating cachetin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am. J. Med. 85, 289-291.
125. Lai, N.-S., Lan, J.-L., Yu, C.-L., and Lin, R.-H. (1995). Role of tumor necrosis factor-a in the regulation of activated synovial T cell growth: Down-regulation of synovial T cells in rheumatoid arthritis patients. Eur. J. Immunol. 25, 3243-3248.
126. Laurence, J. S. (1970). Rheumatoid arthritis: Nature of nurture? Ann. Rheum. Dis. 29, 357-369.
127. Lee, J. C, Laydon, J. T., McDonnell, P. C, Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Strickler, J. E., McLaughlin, M. M., Siemens, I. R., Fisher, S. M., Livi, G. P., White, T. R., Adams, T. L., and Young, P. R. (1994). A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746.
128. Leeuwenberg, J. F., Smeets, E. F., Neefjes, J. J., Shaffer, M. A., Cinek, T., Jeunhomme, T. M., Ahem, T. J., and Buurman, W. A. (1992). E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77, 543-549.
129. LeGoff, P., Koreichi, A., Saraux, A., and Baron, D. (1994). Lymphoma in a patient under low dose methotrexate for rheumatoid arthritis: A new case. Rev. Rheum. 61, 330-331.
130. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309.
131. Lesslauer, W., Tabuchi, H., Gertz, R., Brockhaus, M., Schlaeger, E. J., Graw, G., Piguet, P. F., Pointaire, P. P., Vassili, P., and Loetscher, H. (1991). Recombinant soluble tumor necrosis factor receptor proteins protect from lipopolysaccharide-induced lethality. Eur. J. Immunol. 21, 2883-2886.
132. Lewthwaite, J., Blake, S., Hardingham, T., Foulkes, R., Stephens, S., Chaplin, L., Emtage, S., Catterall, C, Short, S., Nesbitt, A., Allen, R., Bodmer, M., Brown, D., Andrew, D., and Henderson, B. (1995). Role of TNFα in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNFα neutralizing monoclonal antibodies. Ann. Rheum. Dis. 54, 366-374.
133. Liblau, R. S., Singer, S. M., and McDevitt, H. O. (1995). Thl and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16, 34-38.
134. Lipsky, P. E. (1989). The control of antibody production by immunomodulatory molecules. Arthr. Rheum. 32, 1345-1355.
135. Loblay, R. H., Schroer, J., and Rosenthal, A. S. (1980). Attempts at determinant-specific antibody blockade of macrophage presentation. In "Macrophage Regulation of Immunity" (E. R. Unanue and A. S. Rosenthal, Eds.), pp. 87. Academic Press, San Diego.
136. LoBuglio, A. F., Wheeler, R. H., Trang, J., Haynes, A., Rogers, K., Harvey, E. B., Sun, L., Ghrayeb, J., and Khazaeli, M. B. (1989). Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc. Natl. Acad. Sci. USA 86, 4220-4224.
137. Loetscher, H., Pan, Y. C., Lahm, H. W., Gentz, R., Brockhaus, M., Tabuchi, H., and Lesslauer, W. (1990). Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61, 351-359.
138. Londei, M., Savill, C. M., Verhoef, A., Brennan, F., Leech, Z. A., Duance, V., Maini, R. N., and Feldmann, M. (1989). Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 86, 636-640.
139. Lotz, M., Tsoukas, C. D., Robinson, C. A., Dinarello, C. A., Carson, D. A., and Vaughan, J. H. (1986). Basis for defective responses of rheumatoid synovial fluid lymphocytes to anti-CD3 (T3) antibodies. J. Clin. Invest. 78, 713-721.
140. Lotz, M., Kekow, J., and Carson, D. A. (1990). Transforming growth factor-/3 and cellular immune responses in synovial fluids. J. Immunol. 144, 4189-4194.
141. Lukacs, N. W., Chensue, S. W., Strieter, R. M., Warmington, K., and Kunkel, S. L. (1994). Inflammatory granuloma formation is mediated by TNF-alpha-inducible intercellular adhesion molecule-1. J. Immunol. 152, 5883-5889.
142. MacDonald, T. T., Hutchings, P., Choy, M. Y., Murch, S., and Cooke, A. (1990). Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin. Exp. Immunol. 81, 301-305.
143. McCabe, R. P., Woody, J., van Deuerter, S., Targan, S. R., Mayer, L., Ogezand, R., Rutgeerts, P. J., Hanauer, S. B., Podolsky, D., and Elson, C. O. (1996). A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in Crohn's disease. Gastroenterology 110, A940. [abstract 3752]
144. Macgregor, A. J., and Silman, A. (1994). An analysis of the relative contribution of genetic and environmental factors to rheumatoid arthritis susceptibility. Arihr. Rheum. 37, S169.
145. Maini, R. N., Elliott, M. J., Charles, P. J., and Feldmann, M. (1994). Immunological intervention reveals reciprocal roles for TNFα and IL-10 in rheumatoid arthritis and SLE. Springer Sem. Immunopathol. 16, 327-336.
146. Maini, R. N., Chu, C. Q., and Feldmann, M. (1995a). Aetiopathogenesis of rheumatoid arthritis. In "Mechanisms and Models in Rheumatoid Arthritis" (B. Henderson, J. C. W. Edwards, and E. R. Pettipher, Eds.), pp. 25-46. Academic Press, San Diego.
147. Maini, R. N., Elliott, M. J., Brennan, F. M., Williams, R. O., Chu, C. Q., Paleolog, E., Charles, P. J., Taylor, P. C, and Feldmann, M. (1995b). Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol. Rev. 144,195-223.
148. Maini, R. N., Elliott, M. J., Long-Fox, A., Feldmann, M., Kalden, J. R., Antonio, C, Smolen, J. S., Leeb, B., Breedveld, F. C, MacFarlane, J. D., Bijl, H., and Woody, J. N. (1995c). Clinical response of rheumatoid (RA) to anti TNFa (cA2) monoclonal antibody (mab) is related to administered dose and persistence of circulating antibody. Arthr. Rheum. 38, S186. [Abstract]
149. Malyak, M., Swaney, R. E., and Arend, W. P. (1993). Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Arthr. Rheum. 36, 781-789.
150. Mary, J. Y., and Modigliani, R. (1989). Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30, 983-989.
151. Masi, A. T. (1994). Incidence of rheumatoid arthritis: Do the observed age-sex interaction patterns support a role of androgenic-anabolic steroid deficiency in its padiogenesis? Br. J. Rheumatol. 33, 697.
152. Matteson, E. L., Yocum, D. E., St. Clair, E. W., Achkar, A. A., Thakor, M. S., Jacobs, M. R., Hays, A. E., Heitman, C. K., and Johnston, J. M. (1995). Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthr. Rheum. 38, 1187-1193.
153. McGeehan, G. M., Becherer, J. D., Bast, J. R. C, Boyer, C. M., Champion, B., Connolly, K. M., Conway, J. G., Furdon, P., Karp, S., Kidao, S., McElroy, A. B., Nichols, J., Pryzwansky, K. M., Schoenen, F., Sekut, L., Truesdale, A., Verghese, M., Warner, J., and Ways, J. P. (1994). Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 370, 558-561.
154. Meade, T. W. (1995). Fibrinogen in ischaemic heart disease. Eur. Heart J. 16(Suppl. A), 31-35.
155. Means, R. T. J., Olsen, N. J., Krantz, S. B., Dessypris, E. N., Graber, S. E., Stone, W. J., O'Neil, V. L., and Pincus, T. (1989). Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: Clinical and in vitro studies. Arthr. Rheum. 32, 638-642.
156. Michie, H. R., Manogue, K. R., Spriggs, D. R., Revhaug, A., O'Dwyer, S., Dinarello, C. A., Cerami, A., Wolff, S. M., and Wilmore, D. W. (1988). Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318, 1481-1486.
157. Mikecz, K., Giant, T. T., and Poole, A. R. (1987). Immunity to cartilage proteoglycans in BALB/c mice with progressive polyarthritis and ankylosing spondylitis induced by injection of human cartilage proteoglycan. Arthr. Rheum. 30, 306-318.
158. Miossec, P., Naviliat, M., D'Angeac, A. D., Sany, J., and Banchereau, J. (1990). Low levels of interleukin-4 and high levels of transforming growth factor β in rheumatoid synovitis. Arthr. Rheum. 33, 1180-1187.
159. Mohler, K., Sleath, P. R., Fitzner, J. N., Cerretti, D. P., Alderson, M., Kerwar, S. S., Torrance, D. S., Otten-Evans, C, Greenstreet, T., Weerawarna, K., Kronheim, S. R., Petersen, M., Gerhart, M., Kozlosky, C. J., March, C. J., and Black, R. A. (1994). Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370, 218-220.
160. Moore, K. W., O'Garra, A., de Waal Malefyt, R., Vieira, P., and Mosmann, T. R. (1993). Interleukin-10. Annu. Rev. Immunol. 11, 165-190.
161. Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., and Kaplan, G. (1993). Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177, 1675-1680.
162. Moreland, L. W., Margolies, G. R., Heck, L. W., Saway, P. A., Jacobs, C., Beck, C., Blosch, C., and Koopman, W. J. (1994). Soluble tumor necrosis factor receptor (sTNFR): Results of a phase I dose-escalation study in patients with rheumatoid arthritis. Arthr. Rheum. 37, S295.
163. Moreland, L. W., Pratt, P. W., Mayes, M. D., Postlethwaite, A., Weisman, M. H., Schnitzer, T., Lightfoot, R., Calabrese, L., Zelinger, D. J., Woody,J. N., and Koopman, W. J. (1995). Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthr. Rheum. 38, 1581-1588.
164. Nienhuis, R. L. F., and Mandema, E. (1964). A new serum factor in patients with rheumatoid arthritis: The anti-perinuclear factor. Ann. Rheum. Dis. 23, 302-305.
165. Ohmori, V., Wyner, L., Narumi, S., Armstrong, D., Staler, M., and Hamilton, T. A. (1993). Tumor necrosis factor-alpha induces cell type and tissue-specific expression of chemoattractant cytokines in vivo. Am. J. Pathol. 142, 861-870.
166. Ohshima, S., Saeki, Y., Mima, T., Suemera, M., Ishida, M., Shimuzu, M., McCluskey, R., and Kishimoto, T. (1996). Possible mechanism for the long-term efficacy of antiTNFα antibody (cA2) therapy in RA. Arth. Rheum. 39, S242. [abstract 1289]
167. Oliver, S. J., Banquerigo, M. L., and Brahn, E. (1994). Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell. Immunol. 157, 291-299.
168. Paleolog, E. M., Delasalle, S.-A. J., Buurman, W. A., and Feldmann, M. (1994). Functional activities of receptors for tumor necrosis factor-α on human vascular endothelial cells. Blood 84, 2578-2590.
169. Paleolog, E. M., Hunt, M., Elliott, M. J., Woody, J. N., Feldmann, M., and Maini, R. N, (1996). Monoclonal anti-tumour necrosis factor α deactivates vascular endothelium in rheumatoid arthritis. Arthr. Rheum., 39, 1082-1091.
170. Panayi, G. S., Lanchbury, J. S., and Kingsley, G. H. (1992). The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthr. Rheum. 35, 729.
171. Panillo, J. E., and Fauci, A. S. (1979). Mechanism of glucocorticosteroid action in immune processes. Annu. Rev. Pharmacol. Toxicol. 19, 179-201.
172. Paulus, H. E., Egger, M. J., Ward, J. R., Williams, H. J., and The Cooperative Systemic Studies of Rheumatic Diseases Group (1990). Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthr. Rheum. 33, 477-484.
173. Peacock, D. J., Banquerigo, M. L., and Brahn, E. (1992). Angiogenesis inhibition suppresses collagen arthritis. J. Exp. Med. 175, 1135-1138.
174. Pettipher, E. B., Higgs, G. A., and Henderson, B. (1986). Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc. Natl. Acad. Sci. USA 83, 8749-8753.
175. Pigott, R., Dillon, L. P., Hemingway, I. H., and Gearing, A. J. H. (1992). Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem. Biophys. Res. Commun. 187, 584-589.
176. Piguet, P. F., Grau, G. E., Vesin, C, Loetscher, H., Gentz, R., and Lesslauer, W. (1992). Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77,510-514.
177. Pincus, T., Olsen, N. J., Russell, I. J., Wolfe, F., Harris, E. R., Schnitzer, T. J., Boccagno, J. A., and Krantz, S. B. (1990). Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am. J. Med. 89, 161-168.
178. Pincus, T., and Callahan, L. F. (1993). What is the natural history of rheumatoid arthritis? Rheum. Dis. Clin. North Am. 19, 123-151.
179. Plate, K. H., Breier, G., Millauer, B., Ullrich, A., and Risau, W. (1993). Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 53, 5822-5827.
180. Podolsky, D. K. (1991). Inflammatory bowel disease. IV. Engl. J. Med. 325, 928-937.
181. Poli, G., Kinter, A., and Justenment, J. S. (1990). Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc. Natl. Acad. Sci. USA 87, 782-785.
182. Probert, L., Plows, D., Kontogeorgos, G., and Kollias, G. (1995). The type 1 interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur. J. Immunol. 25, 1794-1797.
183. Qin, S. X., Cobbold, S. P., Tighe, H., Benjamin, R., and Waldmann, H. (1987). CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur. J. Immunol. 17, 1559-1165.
184. Ranges, G. E., Sriram, S., and Cooper, S. M. (1985). Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J. Exp. Med. 162, 1105-1110.
185. Rankin, E. C. C, Choy, E. H. S., Kassimos, D., Kingsley, G. H., Sopwith, A. M., Isenberg, D. A., and Panayi, G. S. (1995). The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 34, 334-342.
186. Rathanaswami, P., Hachicha, M., Sadick, M., Schall, T. J., and McColl, S. R. (1993). Expression of die cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J. Biol. Chem. 268, 5834-5839.
187. Reddy, M. M., Sorrell, S. J., Lange, M., and Grieco, M. H. (1988). Tumor necrosis factor and HrV p24 antigen levels in serum of HIV-infected populations. J. Acquir. Immune Deficiency Syndrome 1, 436-440.
188. Ronnelid, J., Lysholm, J., Engstrom-Laurent, A., Klareskog, L., and Heyman, B. (1994). Local anti-type II collagen antibody production in rheumatoid arthritis synovial fluid. Evidence for an HLA-DR4-restricted IgG response. Arthr. Rheum. 37, 1023-1029.
189. Roodman, G. D., Bird, A., Hutzler, D., and Montgomery, W. (1987). Tumor necrosis factor-alpha and hematopoietic progenitors: Effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines k562, HL60, and HEL cells. Exp. Hematol. 15, 928-935.
190. Roux-Lombard, P., Modoux, C, Vischer, T., Grassi, J., and Dayer, J. M. (1992). Inhibitors of interleukin 1 activity in synovial fluids and in cultured synovial fluid mononuclear cells. J. Rheumatol. 19, 517-523.
191. Roux-Lombard, P., Punzi, L., Hasler, F., Bas, S., Todesco, S., Gallati, H., Gueme, P. A., and Dayer, J. M. (1993). Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthr. Rheum. 36, 485-489.
192. Russell, D., Tucker, K., Kohno, H., Thompson, R. C., and Schwab, J. (1994). Inhibition of tumor necrosis factor (TNF) is effective alone or in combination with inhibition of interleukin-1 (IL-1) in reducing joint swelling in rodent bacterial cell wall-induced arthritis. Arthr. Rheum. 37(Suppl.), S279. [Abstract]
193. Saeki, Y., Ohshima, S., Mima, T., Masatoshi, S., Suemura, M., McCloskey, R., Woody, J. N., and Kishimoto, T. (1996). Treatment of patients with refractory rheumatoid arthritis by a chimeric monoclonal antibody to tumor necrosis factor α: An open, uncontrolled clinical trial in Japan. Submitted for publication.
194. Saklatvala, J. (1986). Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322, 547-549.
195. Saklatvala, J., Sarsfield, S. J., and Townsend, Y. (1985). Pig interleukin-1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation and fever. J. Exp. Med. 162, 1208-1215.
196. Sallusto, F., and Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 1109-1118.
197. Sander, O., Herborn, G., and Rau, R. (1995). Tumor necrosis factor alpha (TNF) blockade enhances methotrexate (MTX) response in patients widi rheumatoid arthritis (RA). Arthr. Rheum. 38, S266.
198. Sands, B. E., Podolsk, D. K., Tremeune, W. J., Sanborn, W. J., Rutgeers, P. J., Hanauer, S. B., Mayer, L., Targan, S. R., Dewoody, K. L., Braakman, T. and Woody, J. N. (1996). Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe, steroid refractory ulcerative colitis Gastroenterology 110, A-778. [abstract 3112]
199. Saxne, T., Palladino, M. A., Jr., Heinegard, D., Talal, N., and Wollheim, F. A. (1988). Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthr. Rheum. 31, 1041-1045.
200. Scallon, B. J., Moore, M. A., Trinh, H., Knight, D. M., and Ghrayeb, J. (1995). Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7, 251-259.
201. Schall, T. J., Lewis, M., Roller, K. J., Lee, A., Rice, G. C, Wong, G. H. W., Gatanaga, T., Granger, R., Lentz, R., Raab, H., Kohr, W. J., and Goeddel, D. V. (1990). Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61, 361-370.
202. Schrieber, L. (1994). The endothelium in rheumatoid arthritis. In "Rheumatology" (J. H. Klippel and P. A. Dieppe, Eds.), Section 3, pp. 10.1-10.6. Mosby, London.
203. Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., and Morgan, A., Jr. (1985). Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 45, 879-885.
204. Sebbag, M., Simon, M., Vincent, C, Masson-Bessiere, C, Girbal, E., Jean-Jacques, D., and Serre, E. (1995). The anti-perinuclear factor and the so-called anti-keratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 95, 2672-2679.
205. Semmler, J., Wachtel, H., and Endres, S. (1993). The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int. J. Immunopharmacol. 15, 409-413.
206. Sheehan, K., Ruddle, N. H., and Schreiber, R. D. (1989). Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors.J. Immunol. 142, 3884-3893.
207. Shweiki, D., Neeman, M., Itin, A., and Keshet, E. (1995). Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis. Proc. Natl. Acad. Sci. USA 92, 768-772.
208. Silman, A. J., MacGregor, A. J., Thomson, W., Holligan, S., Carthy, D., Farhan, A., and Oilier, W. E. R. (1993). Twin concordance rates for rheumatoid arthritis: Results from a nationwide study. Br. J. Rheumatol. 32, 903-907.
209. Silman, A. J., and Hochberg, M. C. (1995). "Epidemiology of the Rheumatic Diseases." Oxford University Press, New York.
210. Silverman, H. A., Johnson, J. S., Vaughan, J. H., and McGlamory, J. C. (1976). Altered lymphocyte reactivity in rheumatoid arthritis. Arthr. Rheum. 19, 509-515.
211. Simon, A. K., Seipelt, E., and Sieper, J. (1994). Divergent T-cell cytokine patterns in inflammatory arthritis. Proc. Natl. Acad. Sci. USA 91, 8562-8566.
212. Soloman, L., Robin, G., and Valkenburg, H. A. (1975). Rheumatoid arthritis in an urban South African Negro population. Ann. Rheum. Dis. 34, 128-135.
213. Sommer, N., Loschmann, P.-A., Northoff, G. H., Weller, M., Steinbrecher, A., Steinbach, J. P., Lichtenfels, R., Meyermann, R., Riethmuller, A., Fontana, A., Dichgans, J., and Martin, R. (1995). The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med. 1, 244-248.
214. Stack, W., Mann, S., Roy, A., Heath, P., Sopwith, M., Freeman, J., Holmes, G., Long, R., Forbes, A., Kamm, M., and Hawkey, C. (1996). The effects of CDP571, an engineered human IgG4 anti-TNFα antibody in Crohn's disease. Gastroenterology 110, A284. [abstract 1135]
215. Stasny, P. (1978). Association of the B cell alloantigen DRW4 with rheumatoid arthritis. N Engl. J. Med. 298, 869-871.
216. Tak, P. P., Taylor, P. C., Breedveld, F. C., Smeets, T. J. M., Kluin, P. M., Meinders, A. E., and Maini, R. N. (1996). Reduction in cellularity and expression of adhesion molecules in rheumatoid synovial tissue after anti-TNFα monoclonal antibody treatment. Arthr. Rheum., 39, 1077-1081.
217. Taniguchi, T., Ohno, S., Fujii-Kuriyama, Y., and Muramatsu, H. (1980). The nucleotide sequence of human fibroblast interferon cDNA. Gene 10, 11-15.
218. Targan, S. R., Hanaver, S., van Deuerter, S., Mayer, L., Present, D., Braakman, T., Dewoody, K. L., Schanble, T., Rutgeers, P., and Crohn's Disease Study Group (1997). A double-blind, placebo-controlled dose ranging study of antitumor necrosis factor α chimeric monoclonal antibody (cA2) in the treatment of Crohn's disease, (submitted)
219. Thorbecke, G. J., Shah, R., Leu, C. H., Kuruvilla, A. P., Hardison, A. M., and Palladino, M. A. (1992). Involvement of endogenous tumour necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 89, 7375-7379.
220. Todd, J. A., Acha-Orbea, H., Bell, J. I., Chao, N., Fronek, Z., Jacob, C. O., McDermott, M., Sinha, A. A., Timmerman, L., Steinman, L., and McDevitt, H. O. (1988). A molecular basis for MHC class Il-associated autoimmunity. Science 240, 1003-1009.
221. Trang, J. M. (1992). Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies. In "Protein Pharmacokinetics and Metabolism," pp. 223-264. Plenum Press, New York.
222. Tugwell, P., Bombardier, C, Gent, M., Bennett, K. J., Bensen, W. G., Klinkhoff, A. V., Kraag, G. R., Ludwin, D., and Roberts, R. S. (1990). Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 335, 1051-1055.
223. Van de Lubbe, P. A., Dijkmans, B. A. C., Markusse, H. M., Nassander, U., and Breedveld, F. C. (1995). A randomized double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthr. Rheum. 38, 1097-1106.
224. van den Berg, W. B. (1995). Uncoupling of inflammation and joint destruction in arthritis: Pivotal role of interleukin 1 in destruction. Rheumatol. Eur. 24(Suppl), 161-163.
225. van der Poll, T., and Lowry, S. F. (1995). Tumor necrosis factor in sepsis: Mediator of multiple organ failure or essential part ofhost defense? [editorial]. Shocks, 1-12. [Review]
226. van Deventer, S. J., Buller, H. R., ten Cate, J. W., Aarden, L. A., Hack, C. E., and Sturk, A. (1990). Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76, 2520-2526.
227. van Dullemen, H. M., van Deventer, S. J., Hommes, D. W., Bijl, H. A., Jansen, J., Tytgat, G. N., and Woody, J. (1995). Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129-135.
228. van Gameren, M. M., Willemse, P. H. B., Mulder, N. H., Limburg, P. C., Groen, H. J. M., Vellenga, E., and de Vries, E. G. E. (1994). Effects of recombinant human interleukin-6 in cancer patients: A phase I-II study. Blood 5, 1434-1441.
229. Van Lenten, B. J., Hama, S. Y., de Beer, F. C., Stafforini, D. M., Mclntyre, T. M., Prescott, S. M., La Du, B. N., Fogelman, A. M., and Navab, M. (1995). Anti-inflammatory HDL becomes pro-inflammatory during the active phase response. J. Clin. Invest. 96,2758-2767.
230. Vassalli, P. (1992). The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10, 411-452.
231. 12, and folic acid deficiency, and erythropoietin responsiveness. Ann. Rheum. Dis. 49, 93-98.
232. Waage, A., Halstensen, A., and Espevik, T. (1987). Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1, 355-357.
233. Wahl, S. M. (1994). Transforming growth factor β: The good, the bad, and the ugly. J. Exp. Med. 180, 1587-1590.
234. Waldmann, T. A., Strober, W., and Blaese, R. M. (1970). Variations in the metabolism of immunoglobulins measured by turnover rates, in immunoglobulins. In "Biological Aspects & Clinical Uses" (E. Merler, ed.), pp. 33-51. National Academy of Sciences.
235. Waldmann, H. (1989). Manipulation of T-cell responses with monoclonal antibodies. Annu. Rev. Immunol. 7, 407-444.
236. Weber, J., Yang, J. C, Topalian, S. L., Parkinson, D. R., Schwartzentruber, D. S., Ettinghausen, S. E., Gunn, H., Mixon, A., Kim, H., Cole, D., Levin, R., and Rosenberg, S. A. (1993). Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol. 11, 499.
237. Weigle, W. O. (1973). Immunological unresponsiveness. Adv. Immunol. 16, 61-122.
238. Weinblatt, M. E., Maddison, P. J., Bulpitt, K. J., Hazleman, B. L., Urowitz, M. B., Sturrockk, R. D., Coblyn, J. S., Maier, A. L., Spreen, W. R., Manna, V. K., and Johnston, J. M. (1995). CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. Arthr. Rheum. 38, 1589-1594.
239. Weyand, C. M., and Goronzy, J. J. (1995). Inherited and noninherited risk factors in rheumatoid arthritis. Curr. Opin. Rheumatol. 7, 206-213.
240. Weyand, C. M., Xie, C, and Goronzy, J. J. (1992). Homozygosity for the HLA-DRB1 allele selects for extra-articular manifestations in rheumatoid arthritis. J. Clin. Invest. 89, 2033-2039.
241. Weyand, C. M., McCarthy, T. G., and Goronzy, J. J. (1995). Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis.J. Clin. Invest. 95, 2120-2126.
242. Wherry, J. C, Pennington, J. E., and Wenzel, R. P. (1993). Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies. Crit. Care Med. 21, S436-S440. [Review]
243. Williams, L., Gibbons, D. L., Gearing, A., Maini, R. N., Feldmann, M, and Brennan, F. M. (1996). Paradoxical effects of a synthetic metalloproteinase inhibitor which blocks bodi p55 and p75 TNF receptor shedding and TNFα processing in RA synovial membrane cell cultures. J. Clin. Invest. 97, 2833-2841.
244. Williams, R. O. (1995). Strategies for immune intervention in murine collagen-induced arthritis. PhD thesis, University of London, London.
245. Williams, R. O., Feldmann, M, and Maini, R. N. (1992). Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89, 9784-9788.
246. Williams, R. O., Mason, L. J., Feldmann, M., and Maini, R. N. (1994). Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 91, 2762-2766.
247. Williams, R. O., Ghrayeb, J., Feldmann, M., and Maini, R. N. (1995). Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 84, 433-439.
248. Wilson, A. G., De Vries, N., Pssian, F., van der Putte, L., and Duff, W. (1993). Allelic polymorphism with the human TNFa promoter region is strongly associated with HLAAl, B8 and DR3 alleles.J. Exp. Med. 177, 557-560.
249. Wilson, A. G., Gordon, C, di Giovine, F. S., de Vries, N., van de Putte, L. B. A., Emery, P., and Duff, G. W. (1994). A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur. J. Immunol. 24, 191-195.
250. Winter, G., and Harris, W. J. (1993). Humanized antibodies. Immunol. Today 14, 243-246.
251. Wolfe, F., Mitchell, D. M., Sibley, J. T., Fries, J. F., Bloch, D. B., Williams, C. A., Spitz, P. W., Haga, M., Kleinheksel, S. M., and Cathey, M. A. (1994). The mortality of rheumatoid arthritis. Arthr. Rheum. 37, 481-494.
252. Wooley, P. H., Seibold, J. R., Whalen, J. D., and Chapdelaine, J. M. (1989). Pristaneinduced arthritis. The immunologic and genetic features of an experimental murine model of autoimmune disease. Arthr. Rheum. 32, 1022-1030.
253. Wooley, P. H., Dutcher, J., Widmer, M. B., and Gillis, S. (1993). Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J. Immunol. 151, 6602-6607.
254. Wordsworth, B. P., and Bell, J. I. (1992). The immunogenetics of rheumatoid arthritis. Springer Sem. Immunopathol. 14, 59-78.
255. o0401. Arthr, Rheum. 38, 1744-1753.
256. Wright, J. K., Cawston, T. E., and Hazleman, B. L. (1991). Transforming growth factor beta stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts. Biochim. Biophys. Acta 1094, 207-210.
257. Xu, W. D., Firestein, G. S., Taetle, R., Kaushansky, K., and Zvaifler, N. J. (1989). Cytokines in chronic inflammatory arthritis. J. Clin. Invest. 83, 876-882.
258. Young, B. S. J., Mallya, R. K., Leslie, R. D. G., Clark, C. J. M., and Hamblin, T. J. (1979). Anti-keratin antibodies in rheumatoid arthritis. Med. J. 2, 97-99.